Drugs / TAK-881
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT06935266 | Apr → Sep 2025 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06895967 | Mar → Jul 2025 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05059977 | Oct 2021 → Apr 2022 | — | Takeda | Completed | Met primary |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT05755035 | Oct 2023 → Jan 2026 | immunodeficiency disease | Takeda | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT06747351 | May 2025 → Jun 2028 expected | chronic inflammatory demyelinating polyradiculoneuropathy | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06076642 | Nov 2024 → May 2028 expected | immunodeficiency disease | Takeda | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06955793 Background | — | immunodeficiency disease | Takeda | Available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-04 | Takeda | Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) takeda.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05059977 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).” NCT05755035 ↗ |
| Route | Subcutaneous | “Participants will receive subcutaneous infusion of TAK-881 on Day 1.” NCT05059977 ↗ |